Global Deferiprone Market By Formulation (Tablet, Oral Solution, Capsule), By Indication (Transfusional Iron Overload, NTDT Caused Iron Overload) and By Region and Country – Global Forecast to 2030

Marketresearch.Biz announces publication of its most recently generated research report titled, “Global Deferiprone Market by Formulation (Tablet, Oral Solution, Capsule), By Indication (Transfusional Iron Overload and NTDT Caused Iron Overload), and by Region and Country – Global Forecast to 2030”, which offers a holistic view of the global deferiprone market through systematic segmentation that covers every aspect of the target market.

Request Covid - 19 Impact

The Global Deferiprone Market is projected to be US$ 35.2 Mn in 2020 to reach US$ 37.8 Mn by 2028 at a CAGR of 0.9%.

Deferiprone is an iron chelator specified for the treatment of patients with transfusional iron overload caused owing to thalassemia syndromes, mainly when the current chelation therapy is insufficient. Chelation therapy is utilized to remove the build-up of toxic metals from the body, such as lead, iron, mercury, and arsenic. It prevents patients from getting severe thalassemia symptoms.

Deferiprone, an FDA permitted drug, is majorly utilized to treat transfusion-dependent thalassemia and other related disorders. Deferiprone is a bidentate hydroxypyridone, which has a small molecular weight (139). It forms a stable complex with iron that is then excreted in the urine. It is metabolized by glucuronidation in the liver and has a relatively short half-life of 47-134 minutes, necessitating multiple daily dosing. Deferiprone fallouts in a more substantial reduction in iron levels in those with a difficult iron burden. It might not be as helpful for those with less extensive iron overload. However, this problem can be controlled by increasing Deferiprone's amount administered from 75 to 100 mg/kg/day.

Report Coverage and Deliverables

PDF report and online dashboard will help you understand:

• Competitive benchmarking
• Market forecasts
• Company market shares
• Market opportunities
• Latest trends & dynamics

Request a Free Sample Copy

View Infographic

Global Deferiprone Market Revenue (US$ Mn), 2020–2030

Global deferiprone market is segmented based on formulation, indiaction and region/country. Based on formulation, the market is segmented into tablet, oral solution, and capsule. The oral solution is expected to register the highest CAGR, while the tаblеt ѕеgmеnt ассоuntѕ fоr thе mајоrіtу ѕhаrе іn thе glоbаl dеfеrірrоnе mаrkеt. Based on indiaction, the market is segmented into transfusional iron overload and NTDT caused iron overload. The transfusional iron overload segment in the global deferiprone market is estimated to account for a majority revenue share in 2020 end.

Global Deferiprone Market Attractiveness Analysis by Form, 2014–2030

Increasing prevalence of life-threatening diseases such as thalassemia among the population is anticipated to bolster the growth of the global deferiprone market. Thalassemia affects approximately 4.4 of every 10,000 live births globally, thus growing incidence and prevalence of the disease is estimated to drive consumption of deferiprone.

Rising healthcare spending, predominantly in emerging economies, is also estimated to indirectly affect the market growth of deferiprone. Furthermore, development and focus towards the provision and access to the populace in developing countries is expected to have an optimistic impact on the global deferiprone market

The high cost of branded drugs, as compared to its generic counterparts, is also expected to restrain the growth of the market to a certain extent.

The research report on the Global Deferiprone market includes profiles of some of the major companies such as Cipla Limited., Apotex Inc., Swedish Orphan Biovitrum AB (publ)., Genepharm S.A., Lipomed AG., Drug International Limited., Ambrosia Remedies (P) Ltd., and Focus Pharmaceuticals Limited.

Segmentation of the Global Deferiprone Market:

Segmentation by Formulation:

• Tablet
• Oral Solution
• Capsule

Segmentation by Indication:

• Transfusional Iron Overload
• NTDT Caused Iron Overload

Segmentation by Regions:

• North America
• Europe
• APAC
• South America
• MEA